This website uses cookies, which are necessary for the technical operation of the website and are always set. Other cookies, which increase the comfort when using this website, are used for direct advertising or to facilitate interaction with other websites and social networks, are only set with your consent.
Configuration
Technically required
These cookies are necessary for the basic functions of the shop.
"Allow all cookies" cookie
"Decline all cookies" cookie
CSRF token
Cookie preferences
Currency change
Customer-specific caching
FACT-Finder tracking
Individual prices
Selected shop
Session
Comfort functions
These cookies are used to make the shopping experience even more appealing, for example for the recognition of the visitor.
Note
Show the facebook fanpage in the right blod sidebar
Statistics & Tracking
Affiliate program
Conversion and usertracking via Google Tag Manager
Soluble in DMSO. Acalabrutinib, also known as ACP-196, is an irreversible Bruton tyrosine kinase (BTK) inhibitor. It binds covalently to Cys481 with improved selectivity and in vivo target coverage. Acalabrutinib inhibited BTK with an IC50 of 3 nM and had improved target specificity over ibrutinib with 323-, 94-, 19-, and 9-fold selectivity over the other TEC kinase family members (ITK, TXK, BMX, and TEC, respectively) and no activity against EGFR. Wu J., et al. 'Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.' J. Hematol. Oncol. 9: 21 (2016). Acalabrutinib avoided major platelet dysfunction in non-Hodgkin lymphoma (NHL) patients associated with ibrutinib treatment. Bye A.P., et al. 'Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib. Blood Adv. 1: 2610-2623 (2017). In an uncontrolled, phase 1-2, multicenter study, the selective and irreversible BTK inhibitor acalabrutinib demonstrated promising safety and efficacy profiles in patients with relapsed chronic lymphocytic leukemia (CLL), including those with chromosome 17p13.1 deletion. Byrd J.C., et al. 'Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.' N. Engl. J. Med. 374: 323-332 (2016).
This website uses cookies, which are necessary for the technical operation of the website and are always set. Other cookies, which increase the usability of this website, serve for direct advertising or simplify interaction with other websites and social networks, will only be used with your consent.
More information